News from juventas therapeutics A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 23, 2014, 10:11 ET
Juventas Therapeutics.  (PRNewsFoto/Juventas Therapeutics)

Juventas Therapeutics strengthens leadership team by adding two industry veterans

Juventas Therapeutics, a clinical-stage biotechnology company developing a first-in-class regenerative gene therapy for treatment of heart failure...

May 06, 2014, 09:00 ET
Juventas Therapeutics.  (PRNewsFoto/Juventas Therapeutics)

Juventas Therapeutics to Present Top-Line Interim Results from Phase II STOP-HF Trial in Late-Breaking Oral Presentation at European Society of Cardiology Heart Failure Congress

Juventas Therapeutics today announced that top-line interim data from its ongoing Phase II STOP-HF study will be presented in a late-breaking oral...

Feb 04, 2014, 09:00 ET
Juventas Therapeutics.  (PRNewsFoto/Juventas Therapeutics)

Juventas Therapeutics initiates Phase II RETRO-HF clinical trial enrollment for patients with heart failure

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for the treatment of cardiovascular...

Dec 09, 2013, 09:35 ET
Juventas Therapeutics.  (PRNewsFoto/Juventas Therapeutics)

Juventas Therapeutics initiates first clinical trial for retrograde infusion of a gene therapy to patients with heart failure

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease,...

Oct 28, 2013, 09:00 ET
Juventas Therapeutics.  (PRNewsFoto/Juventas Therapeutics)

Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure

Juventas Therapeutics, a privately-held clinical-stage company developing novel therapies for treatment of cardiovascular disease, announced today...

Jan 28, 2013, 09:00 ET
Juventas Therapeutics Logo.  (PRNewsFoto/Juventas Therapeutics)

Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development

Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease...

Aug 20, 2012, 09:00 ET
Juventas Therapeutics Logo.  (PRNewsFoto/Juventas Therapeutics)

Juventas Therapeutics doses first patient in Phase II STOP-HF trial

Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease,...

Jul 16, 2012, 09:00 ET

Juventas Therapeutics Raises $22.2 Million Series B Financing

 Juventas Therapeutics, a clinical-stage regenerative medicine company, announced today that it has closed a $22.2 million Series B financing...

May 15, 2012, 09:00 ET
Juventas Therapeutics.  (PRNewsFoto/Juventas Therapeutics)

Juventas Therapeutics Enrolling Patients in Phase IIa STOP-CLI Clinical Trial

 Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular...

Jan 30, 2012, 09:00 ET
Juventas Therapeutics.  (PRNewsFoto/Juventas Therapeutics)

Juventas Therapeutics Reports One Year Data From Phase I Heart Failure Clinical Trial

Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular...

May 24, 2011, 13:49 ET

Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit

Juventas Therapeutics is a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease....

Apr 26, 2011, 08:00 ET

Juventas Therapeutics Completes Successful Phase I Clinical Trial for JVS-100 in Treatment of Patients with Heart Failure

Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that it has...

Jan 03, 2011, 08:00 ET

Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia

Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the...

Apr 05, 2010, 08:00 ET

Juventas Therapeutics Enrolling Phase I Clinical Trial of JVS-100 for Patients with Heart Failure

Juventas Therapeutics, a privately held, clinical-stage regenerative medicine company announced it has started enrolling patients in a Phase I...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge